his program unites multidisciplinary experts from Memorial Sloan Kettering Cancer Center and around the world, spanning specialties such as hematology, nephrology, surgery, pathology, immunology, and bioethics. We'll explore critical topics pertaining to the evaluation and management of plasma cell dyscrasia patients being considered for kidney transplantation, including:

• Updates in MGRS pathology and classification;
• The latest developments in clone-directed therapy and outcomes;
• Assessing depth of response;
• Updates on transplant biology and immunology;
• Complications of renal transplantation in patients with plasma cell disease; and
• Fair distribution of a scarce resource and role of living donor transplantation.

Additionally, this symposium will feature a patient and clinician roundtable discussion and a workshop on best practices for distinct disease entities.